MIT Technology Review to host subscriber-only talk on AI-designed viruses with Innovator Under 35
MIT Technology Review will host a subscriber-only event on October 16, 2026, featuring Samuel King, a Bioengineering PhD candidate at Stanford University and one of its Innovators Under 35. King will discuss his work using generative AI to design genetic blueprints for viruses, a breakthrough with implications for drug development and synthetic biology. The conversation will be led by senior AI reporter James O’Donnell.
Editor, Lazyfounder
30 SEC SUMMARY
- MIT Technology Review will host a subscriber-only event on October 16, 2026, featuring Samuel King, a Stanford University PhD candidate and Innovator Under 35.
- King used generative AI to design genetic blueprints for viruses in 2025, a breakthrough in bioengineering and AI.
- The conversation will be led by MIT Technology Review’s senior AI reporter, James O’Donnell.
- This event highlights the growing intersection of AI and biotechnology, with potential implications for drug discovery and synthetic biology.
TABLE OF CONTENTS
KEY HIGHLIGHTS
- Samuel King, a Bioengineering PhD candidate at Stanford University and the Arc Institute, used generative AI to propose genetic blueprints for viruses in 2025.
- King was named one of MIT Technology Review’s Innovators Under 35.
- The event, a subscriber-only conversation, is scheduled for October 16, 2026, at 18:30 BST / 1:30pm EDT / 10:30am PDT.
- James O’Donnell, senior AI reporter at MIT Technology Review, will lead the discussion.
Event details and focus
MIT Technology Review will host a subscriber-only conversation with Samuel King, a Bioengineering PhD candidate at Stanford University and the Arc Institute, on October 16, 2026. The event will explore King’s work using generative AI to design genetic blueprints for viruses, a development first reported in 2025.
According to MIT Technology Review, King was recognized as one of its Innovators Under 35, a list that highlights rising stars in technology and science. His work sits at the intersection of artificial intelligence and bioengineering, with potential applications in drug development, synthetic biology, and beyond.
The discussion will be led by James O’Donnell, a senior AI reporter at MIT Technology Review. Subscribers can join the event at 18:30 BST, 1:30pm EDT, or 10:30am PDT.
AI’s role in bioengineering and biosecurity
The use of AI in bioengineering is not new, but recent advancements have accelerated its applications. For example, Google DeepMind’s SynthID Bio tool was introduced to watermark AI-designed proteins, addressing biosecurity concerns by tracking the origin of synthetic sequences without altering their function. This reflects a broader trend of integrating AI into biotechnology to enhance precision and safety.
King’s work builds on these developments, pushing the boundaries of what generative AI can achieve in designing biological systems. His approach could pave the way for faster, more efficient methods of engineering viruses for therapeutic purposes, such as targeted drug delivery or vaccine development.
Other research in the field has explored how biological age influences transplanted organs. A study from Brigham and Women’s Hospital found that transplanted organs adopt the biological age of their recipients, challenging assumptions about rejuvenation through organ transplants. This underscores the complexity of biological systems and the need for advanced tools like AI to navigate them.
What this means
Lazyfounder analysis — our interpretation, not reported fact.
King’s work is a reminder that AI’s impact is expanding beyond digital domains into the physical and biological realms. For founders and operators in biotech, this signals both opportunity and responsibility. The ability to design genetic blueprints with AI could revolutionize drug discovery, but it also raises questions about safety, ethics, and regulation—especially when dealing with viruses.
The event itself reflects a growing interest in democratizing access to cutting-edge research, even if it remains behind a paywall. For startups, this highlights the importance of engaging with specialized media to share breakthroughs and shape industry conversations. King’s recognition as an Innovator Under 35 also underscores the value of early-career researchers in driving innovation, a trend worth watching for talent scouts and investors.
Key takeaways
- AI-driven bioengineering is advancing rapidly, with applications like virus design demonstrating its potential to transform healthcare and biotechnology.
- Events like this one offer founders and operators insights into emerging technologies and their real-world implications, even if access is limited to subscribers.
- The intersection of AI and biology raises critical questions about ethics, regulation, and biosecurity, which startups in this space must address proactively.
- Early-career innovators like King are playing a key role in shaping the future of AI and biotech, making them valuable targets for collaboration, investment, or hiring.
FAQ
What is the focus of Samuel King’s research?
King’s research uses generative AI to design genetic blueprints for viruses, with potential applications in drug development, synthetic biology, and therapeutic interventions.
Who can attend the MIT Technology Review event?
The event is subscriber-only, meaning only paid subscribers to MIT Technology Review can participate.
Why was Samuel King recognized as an Innovator Under 35?
King was named one of MIT Technology Review’s Innovators Under 35 for his groundbreaking work at the intersection of AI and bioengineering, specifically his use of generative AI to design genetic blueprints for viruses.
How does this work compare to other AI-driven biotech advancements?
King’s work is part of a broader trend of using AI to engineer biological systems. For example, Google DeepMind’s SynthID Bio tool watermarks AI-designed proteins to enhance biosecurity, while other research explores AI’s role in drug discovery and synthetic biology. King’s approach specifically targets virus design, a niche with unique challenges and opportunities.
Related on Lazyfounder
Sources
- MIT Technology Review · 2026-10-09
Roundtables: A Conversation With the Creator of AI-Designed Viruses
This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.
About the author
Editor, Lazyfounder
Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.
More stories by Tarun MottliaGet the LazyFounder Brief
Startup, funding and AI news in a five-minute read. Join the early-access list.
